NEW YORK — There was no significant difference in visual outcomes at 2 years in eyes treated with aflibercept monotherapy compared with eyes treated with bevacizumab first before switching to aflibercept, according to a study.
At the American Society of Retina Specialists annual meeting, Chirag D. Jhaveri, MD, FASRS, presented the results of a randomized multicenter clinical trial that aimed to assess the efficacy of aflibercept monotherapy in eyes with center-involved diabetic macular edema compared with bevacizumab followed by aflibercept, if needed.
“Insurance companies, due to